Lucid Diagnostics Inc. (LUCD)
NASDAQ · Healthcare
Lucid Diagnostics Inc. EBITDA 2021–2025
Lucid Diagnostics Inc. annual/quarterly ebitda history and growth rate from 2021 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Lucid Diagnostics Inc. ebitda for the quarter ending March 31, 2026 was -11.9 M, a 3.05% decrease year-over-year.
- Lucid Diagnostics Inc. ebitda for the twelve months ending March 31, 2026 was -48.2 M.
- Lucid Diagnostics Inc. annual ebitda for 2025 was -48.8 M, a 8.65% increase from 2024.
- Lucid Diagnostics Inc. annual ebitda for 2024 was -44.9 M, a 2.39% decrease from 2023.
- Lucid Diagnostics Inc. annual ebitda for 2023 was -46.0 M, a 15.34% decrease from 2022.
- Lucid Diagnostics Inc. annual ebitda for 2022 was -54.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Lucid Diagnostics Inc. EBITDA — FAQ
Lucid Diagnostics Inc. (LUCD) ebitda over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LUCD's ebitda history?
The chart and table above show Lucid Diagnostics Inc.'s ebitda by year and by quarter, including the growth rate.